Core Insights - Tharimmune has raised approximately $540 million in a private placement to pivot towards a digital asset treasury strategy centered on canton coin [1][2] - The company's stock increased by about 30% following the announcement, while the value of canton coin decreased by 4% [1] Funding and Participation - The funding round included participation from various crypto-native and traditional finance entities such as ARK Invest, Kraken, and the Canton Foundation, marking Tharimmune as the first publicly traded company supported by the Foundation [2] - Clear Street served as the sole placement agent and financial advisor for the offering [5] Use of Proceeds - The proceeds from the funding will be utilized for acquiring canton coin, covering operational costs, and establishing multiple validator nodes on the Canton Network to earn CC rewards [3] Canton Network Overview - The Canton Network, supported by major financial institutions like Goldman Sachs and BNP Paribas, aims to integrate traditional financial infrastructure through interoperable smart contracts and processes over 500,000 daily transactions [4] - Tharimmune's biotech operations will continue under the existing team, with Mark Wendland appointed as CEO to lead the treasury initiative and Mark Toomey as president [4]